Taken together, these results suggested that TRIM46 might cause immunosuppression in ccRCC progression while suggesting that patients with high TRIM46 levels might be more likely to benefit from immune checkpoint inhibitors. This evidence concerns the gene TRIM46 and nonpapillary renal cell carcinoma.